We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “The longer OS with CPX-351 in this subgroup suggests ...
Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.
Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results